Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I've noticed with this that anytime it hits the BOB, the ask drops quite a bit, just need a few hands to move in
We will be very soon imo, based on the way the moves I can see it making a move past a dime during the course of a day no problem
180k shares just got lifed....fake wall...hmmmmm
Ask is really thinning out too
Still only 67.....lots of new investors will be jumpingnon once confirmation of $200m recieved. It changes the company entirely
This board is fairly new as well with not a lot of followers yet once news breaks and a ton of new money floods in we will see a huge upward move
Hiring a legitimate business person with a reputable past is a great move forward. I think things with the Wahana group must be progressing. News of funds being deposited will probably be released very soon
A lot of people are saying that.....won't be surprised if it does tomorrow
Agreed
Totally reasonable....this moves very quickly...could be 1 slap away from it!
Nice finish!! Super stong day too!! Look out .01 here we come!
$NSPX starting another run, volume picking up and green. #2 BOB
I know someone who spoke to Conor Flannery and word is it will be big news coming out...can't say specifics however
NSPX going current Cha Ching!! Sabby management knew what they were doing buying up 40% of the OS here!!
I see .01 this week! Major pressure on the price here! moving up
$NSPX OS maxed and looking to go current....major bagger about to happen....me and my group are loading
Load and hold!!
42 steps to sythesize thapsigargin reduced to 12 steps! https://www.queensu.ca/gazette/media/news-release-queens-university-researchers-successfully-synthesize-cancer-agent-thapsigargin
News Release - Queen's University researchers successfully synthesize cancer agent thapsigargin
Thursday, May 25, 2017
KINGSTON - Queen’s University researchers have successfully synthesized the anticancer agent thapsigargin, which could now open the door to the creation of new cancer drugs.
The team of P. Andrew Evans (Chemistry) and his graduate student Dezhi Chen developed an efficient route to thapsigargin in only 12 steps.
“The first successful synthesis of thapsigargin required 42 steps, which was accomplished by at least 10 co-workers over a 10 year period,” says Dr. Evans. “What Dezhi did is impressive by any measure. He devised a new route to this important agent and successfully implemented his idea to complete a 12 step synthesis in only nine months.”
Thapsigargin was isolated from a wild poisonous plant, which is commonly known as the deadly carrot, in 1978. Despite numerous attempts to synthesize, the complexity of the molecule made it very challenging.
A key feature with thapsigargin is that it kills both slow and fast-growth cancer cells by inhibiting an enzyme that controls essential calcium balance inside cells.
With the anticancer drug Mipsagargin entering late-stage clinical trials, Dr. Evans says “it’s estimated that more than one metric ton of thapsigargin will be required per year.”
The prodrug Mipsagargin is being tested for the treatment of some of most challenging cancers, for example liver, brain, kidney and prostate cancer, thereby making it an exciting prospect.
“The efficient synthesis of this molecule is critical as relying on the isolation from a plant growing in the wild is not a sound strategy,” says Dr. Evans.
“The plant is resistant to cultivation in natural or greenhouse conditions, which coupled to the low yielding and tedious isolation makes our approach a timely development. With our process we can make thapsigargin much more readily available with a more efficient process. We have also opened up this area for the preparation of simplified analogues.”
Dr. Evans confirmed the synthesis of thapsigargin was patented through PARTEQ, the Queen’s University technology transfer office.
The research was recently published in Journal of the American Chemical Society and highlighted in Chemical and Engineering News.
Agreed: Inspyr Therapeutics and Lewis and Clark Pharmaceuticals Complete Merger
Creating Integrated Company with Proprietary Platform, Broad Pipeline, and Significant Drug Development Expertise
Inspyr Therapeutics (OTCQB:NSPXD), a clinical-stage biotechnology company, and Lewis and Clark Pharmaceuticals today announced the successful completion of a merger to create an integrated biotechnology company. The newly combined company creates a second proprietary technology platform, broad capability laboratory facilities, pipeline of therapeutics, and drug development expertise to create value across the business.
“This merger has significantly broadened the opportunities we can pursue, spanning from the discovery of new molecules through clinical development,” said Peter Grebow Ph.D., Chairman of Inspyr. “We believe the proprietary technology platform acquired from Lewis & Clark will generate a series of partnerships or collaborations in the near future. The initial proprietary molecules generated on this platform are expected to have novel development applications in immuno-oncology and inflammation.”
Key strategic benefits of the merger:
Novel proprietary technology platform. The Company now has an industry-leading proprietary technology platform based on adenosine chemistry and biology. From this platform, multiple adenosine receptor modulator-based compounds have been developed and are advancing into preclinical studies to support planned Investigational New Drug (IND) applications. Inspyr is pursuing potential license opportunities to leverage this platform.
Broad pipeline of novel therapies for oncology and inflammation. The Company pipeline of novel proprietary therapies currently includes Mipsagargin, dual A2A/A2B antagonists, A2A antagonists, A2B antagonists, and A2A agonists.
State-of-the-art laboratory facilities. The Company has a fully-equipped, state-of-the-art organic and analytical chemistry laboratories located in Charlottesville, Virginia. We believe the value of these assets is significantly greater than the combined market caps at closing.
Experienced leadership. Inspyr’s team has significant clinical development, translational medicine, and business operations experience in the biopharmaceutical industry. Through this merger, the Company’s expertise has expanded to include preclinical development, toxicology, regulatory filings, adenosine receptor pharmacology, physiology, and molecular biology.
Collaboration Agreements. With broad capabilities, laboratory facilities, and extensive drug discovery and development expertise, Inspyr anticipates the first of a series of licensing/collaboration agreements in Q4 2017.
Potential Stock Exchange Listing. Inspyr expects to complete an uplisting to NASDAQ as soon as practical upon meeting the shareholder equity qualification standard.
Under the merger agreement, Inspyr purchased Lewis and Clark in an all-stock transaction. Pursuant to the terms of the transaction, Lewis and Clark Pharmaceuticals is now a wholly-owned subsidiary of Inspyr and Lewis and Clark stockholders own approximately 50% of Inspyr’s common shares, on an as converted basis. In addition, Bo Jesper Hansen, M.D., Ph.D. is retiring from Inspyr’s Board of Directors and Lewis and Clark Director John Montgomery has been appointed to the Inspyr Board of Directors.
Bid growing baby!!!! lets go NSPX!!
Time to up my bid here! Gonna have another one of those major runs, I can feel it
Once they go current, and show phase 3 details this can hit close to $1. Getting in now is a steal!
Lmao....this is one of the best plays at the moment. They are basically telling the public we are getting $200m. The company providing the $200m is confirming they are providing it.
This should have a minimum $200m market cap
And there it goes....on a dime it takes off 40% at a time...anytime this gets under 5 again I'm gonna mortgage the farm!
Its flying under the radar....great time to buy IMO
Maxed AS and OS....very low float....indication they will need to get current based on last filing. Sabby Management taking up significant postion and all voting shares with Conor Flannery.
Hmmmm....something is about to burst....I say we are going current
Lots of new eyes from the break out baords
Wont be surprised if we see 8s today
Looking good here....after several days of red it looks like a reversal!
Thanks BB much appreciated
Hey, I'd like you, as one of the most followed members on IHUB to weigh in on this.
Another poster here is saying how a RS here would scare everyone off, but we would need to go current, and I say that would bring people in.
Can we get your opinion on that? You can see the previous messages to know what I'm talking about
I wouldn't worry about that, if they need to go current first and people would be rushing in on that news....we already know about the possiblity of a RS, but the going current part would send this up bigtime!
Absolutely not! We already know about the filing, so thats already a possibility and noone seems to care, but if they start to get current.
You agree don't you???
I think we can all agree that going current will be a huge mover for this stock....with its AS bascially maxed and the market cap so low, any breath of going current will send this to multi pennies.
We already are aware of the possibility of a RS, its been filed, and noone is worried about it because it can be a positive as it will then uplist, as well, they need to go current first!
NSPX to the bank!!!!
Sorry dude, I gotta step in and agree with the other guys, if they go current this will be a no brainer buy in
Ask is gonna have to get slapped here if anyone wants shares
I see some solids bids but noone is selling....strong spot here
Agreed...I have never seen a stock move so easily
nice bids happening!!! major support right now. In a short time I think we will blow past pennies
Check all this out! This company has major things going for it! No wonder Sabby Hedge fund took up a major postion in it!
Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Westlake Village, California. It is developing novel prodrug therapeutics for the treatment of cancer. Mipsagargin is its lead agent. Mipsagargin is in human clinical trials for patients with numerous different tumor types. Inspyr Therapeutics’ team has substantial pharmaceutical industry and scientific experience. The Company lists on the OTC Markets Group’s OTCQB.?
?
Mipsagargin (G-202) is a prodrug in human clinical trials for patients with hepatocellular carcinoma (HCC, or liver cancer), glioblastoma (GBM, or brain cancer) and prostate cancer. Mipsagargin has been studied in a Phase 2 clinical trial in patients with hepatocellular carcinoma (liver cancer). It has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in this indication.?
?
Mipsagargin is now undergoing evaluation in an open-label, single-arm, Phase II clinical study in patients with glioblastoma (brain cancer). Furthermore, it is undergoing evaluation in two Phase II clinical pilot studies in patients with prostate and clear cell renal cancer.?
?
Inspyr Therapeutics has started the second development program for Mipsagargin as part of a combination therapeutic approach. This new program focuses on the treatment of gastric cancer.
Inspyr has commenced a preclinical study in gastric cancer PDX tumor models, which express varying levels of PSMA, the target of Mipsagargin. In this initial study, Mipsagargin will undergo evaluation initially in combination with paclitaxel.??
?
In addition, the Company plans to evaluate Mipsagargin in combination with DC101 (Cyramza® surrogate antibody). Paclitaxel and Cyramza® are approved for the treatment of gastric cancer.
Inspyr Therapeutics is developing a novel technology platform. This platform combines a strong therapeutic (thapsigargin) with a patented prodrug delivery system that targets the release of drugs within solid tumors without the side effects of chemotherapeutic agents. The innovative platform technology has the potential to work across a range of drugs that precisely target different cancers.??? ??
??
In May 2017, Inspyr Therapeutics and Lewis and Clark Pharmaceuticals announced that they entered into an agreement to create an integrated company with a proprietary platform driving a pipeline of novel therapeutics. With this agreement, Inspyr Therapeutics will purchase Lewis and Clark in an all-stock transaction. Lewis and Clark Pharmaceuticals is a privately-held biotechnology company.
In October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary compounds generated via the Company’s adenosine receptor modulator (ARM) technology platform. The preclinical study will assess adenosine receptor agonists for the management of atherosclerosis.
Furthermore, in October, Inspyr Therapeutics announced the start of a new investigator-sponsored preclinical study of its proprietary adenosine receptor modulator (ARM) based compounds. The preclinical study is led by Elizabeth Kang, M.D., of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). This study will assess these compounds for the prevention of graft versus host disease (GvHD), a potential side effect of allogeneic stem cell transplants.
Inspyr Therapeutics has fully-equipped, state-of-the-art organic and analytical chemistry laboratories in Charlottesville, Virginia. At these laboratories, a team of chemists and toxicologists have expertise in chemical synthesis and analysis, non-clinical dose formulation, plasma concentration analysis, assay development, and toxicology.